Flora Fertility closes US$5m seed round

Flora Fertility has raised US$5m in seed funding to roll out fertility insurance across the US, with plans to expand into Canada.

The round was led by ManchesterStory, with participation from Slauson & Co., TruStage Ventures, BDC Capital, Marathon Fund, Adara Venture Capital and strategic angel investors. Existing investors include Highline Beta, Everywhere Ventures and Cartography Capital.

Laura McDonald, co-founder of Flora Fertility, said: “Fertility is one of the largest uninsured financial risks people face, yet the system today only offers support once you’re already in crisis and often only if your employer provides it.

“We’re creating a new category where fertility becomes something you can proactively plan for, not just pay for when it’s too late.”

Flora says it is introducing a new InsurTech category with individually owned, portable fertility insurance designed to address a gap in healthcare cover.

The company says it wants to shift fertility from a reactive expense to a proactive, data-driven financial planning tool, using AI, personalised underwriting and risk modelling.

The platform lets people buy coverage without relying on an employer, helping it continue through job changes and different stages of life.

Flora’s policies cover a full range of fertility treatments, including diagnostics, medications, intrauterine insemination and in vitro fertilisation, with entry-level pricing starting at about US$20 a month.

The company estimates that infertility affects one in six people globally, while treatment costs can range from US$30,000 to US$50,000, leaving the vast majority of patients without access to care.

Flora says its platform currently reaches more than 10 million prospective policyholders across North America.

The funding will be used to expand Flora’s underwriting capabilities, scale distribution and further develop its platform as it seeks to establish a new market within women’s health and insurance.

Nicole Gunderson, partner at ManchesterStory, said: “Flora is building something that has never existed before, affordable, portable fertility insurance that meets the next generation of women exactly where they are.

“The InsurTech opportunity here is enormous, and the Flora team has the expertise, technology, and vision to define this category.”

Dr Christy Lane, co-founder of Flora Fertility, added: “Fertility has always been treated as unpredictable and uninsurable, but the data tells a different story.

“The earlier someone can access that coverage, the better their outcomes and the lower their costs, which is what makes this model so powerful.

“We’re turning fertility from a reactive medical expense into a proactive, data-driven financial decision.”